key: cord-0702606-i9pb3gf5 authors: Kahn, Robin; Schmidt, Tobias; Golestani, Karan; Mossberg, Anki; Gullstrand, Birgitta; Bengtsson, Anders A.; Kahn, Fredrik title: Mismatch between circulating cytokines and spontaneous cytokine production by leukocytes in hyperinflammatory COVID‐19 date: 2020-08-13 journal: J Leukoc Biol DOI: 10.1002/jlb.5covbcr0720-310rr sha: 5c4c13e62993c40a3d58b8e0f0701fbdb6f7d298 doc_id: 702606 cord_uid: i9pb3gf5 The disease COVID‐19 has developed into a worldwide pandemic. Hyperinflammation and high levels of several cytokines, for example, IL‐6, are observed in severe COVID‐19 cases. However, little is known about the cellular origin of these cytokines. Here, we investigated whether circulating leukocytes from patients with COVID‐19 had spontaneous cytokine production. Patients with hyperinflammatory COVID‐19 (n = 6) and sepsis (n = 3) were included at Skåne University Hospital, Sweden. Healthy controls were also recruited (n = 5). Cytokines were measured in COVID‐19 and sepsis patients using an Immulite immunoassay system. PBMCs were cultured with brefeldin A to allow cytokine accumulation. In parallel, LPS was used as an activator. Cells were analyzed for cytokines and surface markers by flow cytometry. High levels of IL‐6 and measurable levels of IL‐8 and TNF, but not IL‐1β, were observed in COVID‐19 patients. Monocytes from COVID‐19 patients had spontaneous production of IL‐1β and IL‐8 (P = 0.0043), but not of TNF and IL‐6, compared to controls. No spontaneous cytokine production was seen in lymphocytes from either patients or controls. Activation with LPS resulted in massive cytokine production by monocytes from COVID‐19 patients and healthy controls, but not from sepsis patients. Finally, monocytes from COVID‐19 patients produced more IL‐1β than from healthy controls (P = 0.0087) when activated. In conclusion, monocytes contribute partly to the ongoing hyperinflammation by production of IL‐1β and IL‐8. Additionally, they are responsive to further activation. This data supports the notion of IL‐1β blockade in treatment of COVID‐19. However, the source of the high levels of IL‐6 remains to be determined. (www.clinicaltrials.gov). However, the primary cellular source of the circulating cytokines is unknown. Circulating immune cells, primarily monocytes, are generally considered as potent cytokine producers, including cytokines such as IL-1 , IL-6, and TNF. In sepsis, high levels of proinflammatory cytokines are observed in plasma but circulating leukocytes do not seem to be the major cellular source. 3 In addition, monocytes from septic patients seem unresponsive to further activation of cytokine production using LPS. 3 This so called immunoparalysis is thought to contribute to the secondary infections and complications after sepsis. 4 In hyperinflammatory COVID-19 patients, high levels of circulating cytokines are measured but little is known concerning the contribution of circulating leukocytes to cytokine production. Thus, we investigated spontaneous cytokine production by monocytes, T and B cells from COVID-19 patients with hyperinflammation. Fig. S3A and C). Next we investigated the cytokine production in response to stimulation. Upon activation with LPS, a massive production of all measured cytokines was observed in both COVID-19 patients as well as in healthy controls, but not in septic patients (Fig. 1C ). Interestingly enough, the production of IL-1 was specifically increased in COVID- The response of T cells was also studied. Activation using PMA and ionomycin resulted in production (median percentage positive cells) of IL-1 (6.9) and TNF (59.3) by T cells in COVID-19 patients (n = 4), but neither IL-6 nor IL-8 was produced (Supporting Information Fig. S3B and D). PMA and ionomycin activation could not be performed in two patients with COVID-19. We also investigated the contribution of cells negative for the cell markers CD3, CD14, and CD19, to cytokine production (Supporting Information Fig. S4 ). We did not find any noticeable cytokine production by this population, either spontaneous or upon LPS activation. This population consists of several cell types, for example, NK cells and basophils. However, this population of heterogeneous cells do not account for the observed high circulating levels of IL-6 in COVID-19 patients. Here, we describe a mismatch between circulating levels of cytokines and spontaneous cytokine production by leukocytes from COVID-19 patients. We specifically analyzed monocytes, T and B cells, and found that monocytes spontaneously produced IL-1 and IL-8, but to our surprise, only minimal amounts of IL-6 or TNF were produced, although the patients display elevated levels of circulating IL- (C) Activation of cytokine production using LPS resulted in massive production of all cytokines by monocytes in COVID-19 and control PBMCs, but markedly less in monocytes from septic patients. Line at median. Statistical analysis between groups were tested with the Mann-Whitney U-test has been proposed. 29 Many patients with severe COVID-19 develop thromboembolic events, 30 suggesting endothelial activation. Previous studies on cytokine production by circulating PBMCs have been conflicting both demonstrating both a lack of IL-6 as well as IL-8 production in PBMCs, 31 whereas another study, only investigating IL-6 and TNF found increased production of IL-6 by both monocytes and T cells. 32 In addition, we found that monocytes from COVID-19 patients retain their capacity to produce IL-1 , IL-6, IL-8, and TNF when stimulated by LPS. In accordance to our results, a recently published article showed that PBMCs from COVID-19 patients retained their capacity to produce IL-1 , IL-6, and TNF when stimulated by LPS, in contrast to PBMCs from patients with bacterial pneumonia or H1N1. 33 However, neither the cellular origin of the cytokines nor the spontaneous cytokine production was addressed in that study. Importantly, our results indicate a hyperresponsiveness with The authors declare no conflicts of interest. CoV-2: a storm is raging Cytokine storm in COVID-19 and treatment Circulating monocytes are not the major source of plasma cytokines in patients with sepsis Severe sepsis and septic shock Development of endotoxin tolerance in humans in vivo Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach Pathophysiology of endotoxin tolerance: mechanisms and clinical consequences Sepsis induces a long-lasting state of trained immunity in bone marrow monocytes Loss of monocyte metabolic plasticity in endotoxin tolerance: a model for understanding sepsis-induced immune paralysis Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock Endotoxin tolerance: new mechanisms, molecules and clinical significance Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients Induction of endotoxin tolerance in vivo inhibits activation of IRAK4 and increases negative regulators IRAK-M, SHIP-1, and A20 The immunopathology of sepsis and potential therapeutic targets The effects of CD14 and IL-27 on induction of endotoxin tolerance in human monocytes and macrophages Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis Cellular metabolism of myeloid cells in sepsis Endotoxin-induced immunotolerance is associated with loss of monocyte metabolic plasticity and reduction of oxidative burst Molecular mechanism responsible for the priming of macrophage activation Super-low dose endotoxin pre-conditioning exacerbates sepsis mortality Pretreatment of low-dose and super-low-dose LPS on the production of in vitro LPS-induced inflammatory mediators Monocyte deactivation in septic patients: restoration by IFN-gamma treatment Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study Treatment with acetylsalicylic acid reverses endotoxin tolerance in humans in vivo: a randomized placebo-controlled study Endotoxin tolerance represents a distinctive state of alternative polarization (M2) in human mononuclear cells Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB Human monocytes undergo functional re-programming during sepsis mediated by hypoxiainducible factor-1 Receptor-interacting protein 140 orchestrates the dynamics of macrophage M1/M2 polarization SARS-CoV-2 and viral sepsis: observations and hypotheses Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients Complex immune dysregulation in COVID-19 patients with severe respiratory failure Evaluation of nine commercial SARS-CoV-2 immunoassays Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Additional information may be found online in the Supporting Information section at the end of the article.